Anthem Biosciences Limited (ANTHEM) Q2 FY27 Financial Results: PAT ₹1,199 Cr & Revenue ₹4,182 Cr(3 announcements)

Anthem Biosciences reported consolidated revenue of ₹4,182 Mn for Q1FY27, down 22.6% YoY, with EBITDA at ₹1,755 Mn (39.6% margin) and PAT at ₹1,199 Mn (27.1% margin). CRDMO revenue was ₹3,408 Mn, Specialty Ingredients ₹774 Mn, and Other Income ₹249 Mn. PAT declined 11.7% YoY but improved from prior quarter. The company highlighted timing shifts in customer deliveries and sustained demand, with management targeting margin expansion through cost efficiencies and yield optimization. Forward-looking statements were included in the release.

Anthem Biosciences reported consolidated revenue of ₹4,182 crores for Q1FY27, down 22.6% YoY, with EBITDA at ₹1,755 crores and PAT at ₹1,199 crores. EBITDA margin improved to 39.6% from 38.1% YoY, while PAT margin stood at 27.1%. Net cash position was ₹17,197 crores as of June 30, 2026. The company highlighted strong demand and margin discipline despite revenue headwinds.

Anthem Biosciences reported Q1FY27 consolidated revenue of ₹4,182 Mn, down 22.6% YoY, with EBITDA at ₹1,755 Mn (39.6% margin) and PAT at ₹1,199 Mn (27.1% margin). The company highlighted CRDMO revenue of ₹3,408 Mn and specialty ingredients at ₹774 Mn, while noting other income of ₹249 Mn and a PAT margin improvement from prior quarters.